Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Impact of intensive care unit supportive care on the physiology of Ebola virus disease in a universally lethal non-human primate model.

Poliquin G, Funk D, Jones S, Tran K, Ranadheera C, Hagan M, Tierney K, Grolla A, Dhaliwal A, Bello A, Leung A, Nakamura C, Kobasa D, Falzarano D, Garnett L, Bovendo HF, Feldmann H, Kesselman M, Hansen G, Gren J, Risi G, Biondi M, Mortimer T, Racine T, Deschambault Y, Aminian S, Edmonds J, Sourette R, Allan M, Rondeau L, Hadder S, Press C, DeGraff C, Kucas S, Cook BWM, Hancock BJ, Kumar A, Soni R, Schantz D, McKitrick J, Warner B, Griffin BD, Qiu X, Kobinger GP, Safronetz D, Stein D, Cutts T, Kenny J, Soule G, Kozak R, Theriault S, Menec L, Vendramelli R, Higgins S, Liu G, Rahim NM, Kasloff S, Sloan A, He S, Tailor N, Gray M, Strong JE.

Intensive Care Med Exp. 2019 Sep 13;7(1):54. doi: 10.1186/s40635-019-0268-8.

PMID:
31520194
2.

Establishment of an RNA polymerase II-driven reverse genetics system for Nipah virus strains from Malaysia and Bangladesh.

Griffin BD, Leung A, Chan M, Warner BM, Ranadheera C, Tierney K, Audet J, Frost KL, Safronetz D, Embury-Hyatt C, Booth SA, Kobasa D.

Sci Rep. 2019 Aug 1;9(1):11171. doi: 10.1038/s41598-019-47549-y.

3.

Pathogenicity of Nipah henipavirus Bangladesh in a swine host.

Kasloff SB, Leung A, Pickering BS, Smith G, Moffat E, Collignon B, Embury-Hyatt C, Kobasa D, Weingartl HM.

Sci Rep. 2019 Mar 26;9(1):5230. doi: 10.1038/s41598-019-40476-y.

4.

Generation and Characterization of Anti-Filovirus Nucleoprotein Monoclonal Antibodies.

Rahim MN, Wang M, Wang T, He S, Griffin BD, Kobasa D, Yang R, Du Z, Qiu X.

Viruses. 2019 Mar 14;11(3). pii: E259. doi: 10.3390/v11030259.

5.

A Diacylglycerol Kinase Inhibitor, R-59-022, Blocks Filovirus Internalization in Host Cells.

Stewart CM, Dorion SS, Ottenbrite MAF, LeBlond ND, Smith TKT, Qiu S, Fullerton MD, Kobasa D, Côté M.

Viruses. 2019 Mar 1;11(3). pii: E206. doi: 10.3390/v11030206.

6.

Development and Characterization of a Sin Nombre Virus Transmission Model in Peromyscus maniculatus.

Warner BM, Stein DR, Griffin BD, Tierney K, Leung A, Sloan A, Kobasa D, Poliquin G, Kobinger GP, Safronetz D.

Viruses. 2019 Feb 21;11(2). pii: E183. doi: 10.3390/v11020183.

7.

In Vivo Delivery of Synthetic Human DNA-Encoded Monoclonal Antibodies Protect against Ebolavirus Infection in a Mouse Model.

Patel A, Park DH, Davis CW, Smith TRF, Leung A, Tierney K, Bryan A, Davidson E, Yu X, Racine T, Reed C, Gorman ME, Wise MC, Elliott STC, Esquivel R, Yan J, Chen J, Muthumani K, Doranz BJ, Saphire EO, Crowe JE, Broderick KE, Kobinger GP, He S, Qiu X, Kobasa D, Humeau L, Sardesai NY, Ahmed R, Weiner DB.

Cell Rep. 2018 Nov 13;25(7):1982-1993.e4. doi: 10.1016/j.celrep.2018.10.062.

8.

The interaction between the Nipah virus nucleocapsid protein and phosphoprotein regulates virus replication.

Ranadheera C, Proulx R, Chaiyakul M, Jones S, Grolla A, Leung A, Rutherford J, Kobasa D, Carpenter M, Czub M.

Sci Rep. 2018 Oct 30;8(1):15994. doi: 10.1038/s41598-018-34484-7.

9.

Naturally Occurring Single Mutations in Ebola Virus Observably Impact Infectivity.

Wong G, He S, Leung A, Cao W, Bi Y, Zhang Z, Zhu W, Wang L, Zhao Y, Cheng K, Liu D, Liu W, Kobasa D, Gao GF, Qiu X.

J Virol. 2018 Dec 10;93(1). pii: e01098-18. doi: 10.1128/JVI.01098-18. Print 2019 Jan 1.

10.

Efficacy of Ebola Glycoprotein-Specific Equine Polyclonal Antibody Product Against Lethal Ebola Virus Infection in Guinea Pigs.

Chan M, Holtsberg FW, Vu H, Howell KA, Leung A, Van der Hart E, Walz PH, Aman MJ, Kodihalli S, Kobasa D.

J Infect Dis. 2018 Nov 22;218(suppl_5):S603-S611. doi: 10.1093/infdis/jiy329.

PMID:
29955852
11.

The Makona Variant of Ebola Virus Is Highly Lethal to Immunocompromised Mice and Immunocompetent Ferrets.

Wong G, Leung A, He S, Cao W, De La Vega MA, Griffin BD, Soule G, Kobinger GP, Kobasa D, Qiu X.

J Infect Dis. 2018 Nov 22;218(suppl_5):S466-S470. doi: 10.1093/infdis/jiy141.

PMID:
29878131
12.

Comprehending a Killer: The Akt/mTOR Signaling Pathways Are Temporally High-Jacked by the Highly Pathogenic 1918 Influenza Virus.

Ranadheera C, Coombs KM, Kobasa D.

EBioMedicine. 2018 Jun;32:142-163. doi: 10.1016/j.ebiom.2018.05.027. Epub 2018 Jun 2.

13.

Ebola virus requires phosphatidylinositol (3,5) bisphosphate production for efficient viral entry.

Qiu S, Leung A, Bo Y, Kozak RA, Anand SP, Warkentin C, Salambanga FDR, Cui J, Kobinger G, Kobasa D, Côté M.

Virology. 2018 Jan 1;513:17-28. doi: 10.1016/j.virol.2017.09.028. Epub 2017 Oct 12.

14.

Human polyclonal antibodies produced in transchromosomal cattle prevent lethal Zika virus infection and testicular atrophy in mice.

Stein DR, Golden JW, Griffin BD, Warner BM, Ranadheera C, Scharikow L, Sloan A, Frost KL, Kobasa D, Booth SA, Josleyn M, Ballantyne J, Sullivan E, Jiao JA, Wu H, Wang Z, Hooper JW, Safronetz D.

Antiviral Res. 2017 Oct;146:164-173. doi: 10.1016/j.antiviral.2017.09.005. Epub 2017 Sep 8.

PMID:
28893603
15.

DNA vaccination protects mice against Zika virus-induced damage to the testes.

Griffin BD, Muthumani K, Warner BM, Majer A, Hagan M, Audet J, Stein DR, Ranadheera C, Racine T, De La Vega MA, Piret J, Kucas S, Tran KN, Frost KL, De Graff C, Soule G, Scharikow L, Scott J, McTavish G, Smid V, Park YK, Maslow JN, Sardesai NY, Kim JJ, Yao XJ, Bello A, Lindsay R, Boivin G, Booth SA, Kobasa D, Embury-Hyatt C, Safronetz D, Weiner DB, Kobinger GP.

Nat Commun. 2017 Jun 7;8:15743. doi: 10.1038/ncomms15743.

16.

Delivering Prolonged Intensive Care to a Non-human Primate: A High Fidelity Animal Model of Critical Illness.

Poliquin PG, Biondi M, Ranadheera C, Hagan M, Bello A, Racine T, Allan M, Funk D, Hansen G, Hancock BJ, Kesselman M, Mortimer T, Kumar A, Jones S, Leung A, Grolla A, Tran KN, Tierney K, Qiu X, Kobasa D, Strong JE.

Sci Rep. 2017 Apr 26;7(1):1204. doi: 10.1038/s41598-017-01107-6.

17.

The Disinfection Characteristics of Ebola Virus Outbreak Variants.

Cook BW, Cutts TA, Nikiforuk AM, Leung A, Kobasa D, Theriault SS.

Sci Rep. 2016 Dec 2;6:38293. doi: 10.1038/srep38293.

18.

Reduction of Neuraminidase Activity Exacerbates Disease in 2009 Pandemic Influenza Virus-Infected Mice.

Ranadheera C, Hagan MW, Leung A, Collignon B, Cutts T, Theriault S, Embury-Hyatt C, Kobasa D.

J Virol. 2016 Oct 14;90(21):9931-9941. doi: 10.1128/JVI.01188-16. Print 2016 Nov 1.

19.

Limited Effects of Type I Interferons on Kyasanur Forest Disease Virus in Cell Culture.

Cook BW, Ranadheera C, Nikiforuk AM, Cutts TA, Kobasa D, Court DA, Theriault SS.

PLoS Negl Trop Dis. 2016 Aug 1;10(8):e0004871. doi: 10.1371/journal.pntd.0004871. eCollection 2016 Aug.

20.

Rapid one-step construction of a Middle East Respiratory Syndrome (MERS-CoV) infectious clone system by homologous recombination.

Nikiforuk AM, Leung A, Cook BWM, Court DA, Kobasa D, Theriault SS.

J Virol Methods. 2016 Oct;236:178-183. doi: 10.1016/j.jviromet.2016.07.022. Epub 2016 Jul 25.

21.

Post-exposure treatment with whole inactivated H5N1 avian influenza virus protects against lethal homologous virus infection in mice.

Hagan M, Ranadheera C, Audet J, Morin J, Leung A, Kobasa D.

Sci Rep. 2016 Jul 12;6:29433. doi: 10.1038/srep29433.

22.

Development of a subgenomic clone system for Kyasanur Forest disease virus.

Cook BWM, Nikiforuk AM, Cutts TA, Kobasa D, Court DA, Theriault SS.

Ticks Tick Borne Dis. 2016 Jul;7(5):1047-1051. doi: 10.1016/j.ttbdis.2016.06.002. Epub 2016 Jun 10.

PMID:
27357207
23.

Avian influenza viruses that cause highly virulent infections in humans exhibit distinct replicative properties in contrast to human H1N1 viruses.

Simon PF, de La Vega MA, Paradis É, Mendoza E, Coombs KM, Kobasa D, Beauchemin CAA.

Sci Rep. 2016 Apr 15;6:24154. doi: 10.1038/srep24154.

24.

Pathobiological Characterization of a Novel Reassortant Highly Pathogenic H5N1 Virus Isolated in British Columbia, Canada, 2015.

Berhane Y, Kobasa D, Embury-Hyatt C, Pickering B, Babiuk S, Joseph T, Bowes V, Suderman M, Leung A, Cottam-Birt C, Hisanaga T, Pasick J.

Sci Rep. 2016 Mar 18;6:23380. doi: 10.1038/srep23380.

25.

Ebola viral load at diagnosis associates with patient outcome and outbreak evolution.

de La Vega MA, Caleo G, Audet J, Qiu X, Kozak RA, Brooks JI, Kern S, Wolz A, Sprecher A, Greig J, Lokuge K, Kargbo DK, Kargbo B, Di Caro A, Grolla A, Kobasa D, Strong JE, Ippolito G, Van Herp M, Kobinger GP.

J Clin Invest. 2015 Dec;125(12):4421-8. doi: 10.1172/JCI83162. Epub 2015 Nov 9.

26.

Development and Characterization of a Guinea Pig-Adapted Sudan Virus.

Wong G, He S, Wei H, Kroeker A, Audet J, Leung A, Cutts T, Graham J, Kobasa D, Embury-Hyatt C, Kobinger GP, Qiu X.

J Virol. 2015 Oct 21;90(1):392-9. doi: 10.1128/JVI.02331-15. Print 2016 Jan 1.

27.

Highly Pathogenic H5N1 and Novel H7N9 Influenza A Viruses Induce More Profound Proteomic Host Responses than Seasonal and Pandemic H1N1 Strains.

Simon PF, McCorrister S, Hu P, Chong P, Silaghi A, Westmacott G, Coombs KM, Kobasa D.

J Proteome Res. 2015 Nov 6;14(11):4511-23. doi: 10.1021/acs.jproteome.5b00196. Epub 2015 Oct 9.

PMID:
26381135
28.

Hemagglutinin-Neuraminidase Balance Influences the Virulence Phenotype of a Recombinant H5N3 Influenza A Virus Possessing a Polybasic HA0 Cleavage Site.

Diederich S, Berhane Y, Embury-Hyatt C, Hisanaga T, Handel K, Cottam-Birt C, Ranadheera C, Kobasa D, Pasick J.

J Virol. 2015 Nov;89(21):10724-34. doi: 10.1128/JVI.01238-15. Epub 2015 Aug 5.

29.

Randomized controlled ferret study to assess the direct impact of 2008-09 trivalent inactivated influenza vaccine on A(H1N1)pdm09 disease risk.

Skowronski DM, Hamelin ME, De Serres G, Janjua NZ, Li G, Sabaiduc S, Bouhy X, Couture C, Leung A, Kobasa D, Embury-Hyatt C, de Bruin E, Balshaw R, Lavigne S, Petric M, Koopmans M, Boivin G.

PLoS One. 2014 Jan 27;9(1):e86555. doi: 10.1371/journal.pone.0086555. eCollection 2014.

30.

Vectored expression of the broadly neutralizing antibody FI6 in mouse airway provides partial protection against a new avian influenza A virus, H7N9.

Limberis MP, Racine T, Kobasa D, Li Y, Gao GF, Kobinger G, Wilson JM.

Clin Vaccine Immunol. 2013 Dec;20(12):1836-7. doi: 10.1128/CVI.00545-13. Epub 2013 Oct 16. No abstract available.

31.

Development of neutralizing monoclonal antibodies against the pandemic H1N1 virus (2009) using plasmid DNA immunogen.

Cabral TM, Baig A, Berhane Y, Schmidt L, Hole K, Leith M, Kobasa D, Corbett CR.

J Virol Methods. 2014 Jan;195:54-62. doi: 10.1016/j.jviromet.2013.08.038. Epub 2013 Sep 20.

PMID:
24060631
32.

Intranasal antibody gene transfer in mice and ferrets elicits broad protection against pandemic influenza.

Limberis MP, Adam VS, Wong G, Gren J, Kobasa D, Ross TM, Kobinger GP, Tretiakova A, Wilson JM.

Sci Transl Med. 2013 May 29;5(187):187ra72. doi: 10.1126/scitranslmed.3006299.

33.

A (H1N1) pdm09 HA D222 variants associated with severity and mortality in patients during a second wave in Mexico.

Vazquez-Perez JA, Isa P, Kobasa D, Ormsby CE, Ramírez-Gonzalez JE, Romero-Rodríguez DP, Ranadheera C, Li Y, Bastien N, Embury-Hyatt C, González-Duran E, Barrera-Badillo G, Ablanedo-Terrazas Y, Sevilla-Reyes EE, Escalera-Zamudio M, Cobián-Güemes AG, Lopez I, Ortiz-Alcántara J, Alpuche-Aranda C, Perez-Padilla JR, Reyes-Terán G.

Virol J. 2013 Jan 31;10:41. doi: 10.1186/1743-422X-10-41.

34.

Prior infection of chickens with H1N1 or H1N2 avian influenza elicits partial heterologous protection against highly pathogenic H5N1.

Nfon C, Berhane Y, Pasick J, Embury-Hyatt C, Kobinger G, Kobasa D, Babiuk S.

PLoS One. 2012;7(12):e51933. doi: 10.1371/journal.pone.0051933. Epub 2012 Dec 11.

35.

Prior infection of chickens with H1N1 avian influenza virus elicits heterologous protection against highly pathogenic H5N2.

Nfon C, Berhane Y, Pasick J, Kobinger G, Kobasa D, Babiuk S.

Vaccine. 2012 Nov 26;30(50):7187-92. doi: 10.1016/j.vaccine.2012.10.021. Epub 2012 Oct 19.

PMID:
23084852
36.

Recently emerged swine influenza A virus (H2N3) causes severe pneumonia in Cynomolgus macaques.

Richt JA, Rockx B, Ma W, Feldmann F, Safronetz D, Marzi A, Kobasa D, Strong JE, Kercher L, Long D, Gardner D, Brining D, Feldmann H.

PLoS One. 2012;7(7):e39990. doi: 10.1371/journal.pone.0039990. Epub 2012 Jul 11.

37.

Co-administration of certain DNA vaccine combinations expressing different H5N1 influenza virus antigens can be beneficial or detrimental to immune protection.

Patel A, Gray M, Li Y, Kobasa D, Yao X, Kobinger GP.

Vaccine. 2012 Jan 11;30(3):626-36. doi: 10.1016/j.vaccine.2011.11.017. Epub 2011 Nov 23.

PMID:
22119588
38.

The 2009 pandemic H1N1 D222G hemagglutinin mutation alters receptor specificity and increases virulence in mice but not in ferrets.

Abed Y, Pizzorno A, Hamelin ME, Leung A, Joubert P, Couture C, Kobasa D, Boivin G.

J Infect Dis. 2011 Oct 1;204(7):1008-16. doi: 10.1093/infdis/jir483.

PMID:
21881115
39.

Cellular immune response in the presence of protective antibody levels correlates with protection against 1918 influenza in ferrets.

Pillet S, Kobasa D, Meunier I, Gray M, Laddy D, Weiner DB, von Messling V, Kobinger GP.

Vaccine. 2011 Sep 9;29(39):6793-801. doi: 10.1016/j.vaccine.2010.12.059. Epub 2011 Jan 4.

PMID:
21211587
40.

Pandemic swine-origin H1N1 influenza A virus isolates show heterogeneous virulence in macaques.

Safronetz D, Rockx B, Feldmann F, Belisle SE, Palermo RE, Brining D, Gardner D, Proll SC, Marzi A, Tsuda Y, Lacasse RA, Kercher L, York A, Korth MJ, Long D, Rosenke R, Shupert WL, Aranda CA, Mattoon JS, Kobasa D, Kobinger G, Li Y, Taubenberger JK, Richt JA, Parnell M, Ebihara H, Kawaoka Y, Katze MG, Feldmann H.

J Virol. 2011 Feb;85(3):1214-23. doi: 10.1128/JVI.01848-10. Epub 2010 Nov 17.

41.

Quantitative proteomic analyses of influenza virus-infected cultured human lung cells.

Coombs KM, Berard A, Xu W, Krokhin O, Meng X, Cortens JP, Kobasa D, Wilkins J, Brown EG.

J Virol. 2010 Oct;84(20):10888-906. doi: 10.1128/JVI.00431-10. Epub 2010 Aug 11.

42.

Potent vesicular stomatitis virus-based avian influenza vaccines provide long-term sterilizing immunity against heterologous challenge.

Schwartz JA, Buonocore L, Suguitan AL Jr, Silaghi A, Kobasa D, Kobinger G, Feldmann H, Subbarao K, Rose JK.

J Virol. 2010 May;84(9):4611-8. doi: 10.1128/JVI.02637-09. Epub 2010 Feb 24.

43.

Assessment of the efficacy of commercially available and candidate vaccines against a pandemic H1N1 2009 virus.

Kobinger GP, Meunier I, Patel A, Pillet S, Gren J, Stebner S, Leung A, Neufeld JL, Kobasa D, von Messling V.

J Infect Dis. 2010 Apr 1;201(7):1000-6. doi: 10.1086/651171.

PMID:
20170374
44.

Lethal influenza virus infection in macaques is associated with early dysregulation of inflammatory related genes.

Cillóniz C, Shinya K, Peng X, Korth MJ, Proll SC, Aicher LD, Carter VS, Chang JH, Kobasa D, Feldmann F, Strong JE, Feldmann H, Kawaoka Y, Katze MG.

PLoS Pathog. 2009 Oct;5(10):e1000604. doi: 10.1371/journal.ppat.1000604. Epub 2009 Oct 2.

45.

Evaluation of conserved and variable influenza antigens for immunization against different isolates of H5N1 viruses.

Patel A, Tran K, Gray M, Li Y, Ao Z, Yao X, Kobasa D, Kobinger GP.

Vaccine. 2009 May 18;27(23):3083-9. doi: 10.1016/j.vaccine.2009.03.023. Epub 2009 Apr 1.

PMID:
19428922
46.

Intranasal administration of alpha interferon reduces seasonal influenza A virus morbidity in ferrets.

Kugel D, Kochs G, Obojes K, Roth J, Kobinger GP, Kobasa D, Haller O, Staeheli P, von Messling V.

J Virol. 2009 Apr;83(8):3843-51. doi: 10.1128/JVI.02453-08. Epub 2009 Feb 4.

47.

Proteolytic activation of the 1918 influenza virus hemagglutinin.

Chaipan C, Kobasa D, Bertram S, Glowacka I, Steffen I, Tsegaye TS, Takeda M, Bugge TH, Kim S, Park Y, Marzi A, Pöhlmann S.

J Virol. 2009 Apr;83(7):3200-11. doi: 10.1128/JVI.02205-08. Epub 2009 Jan 21.

48.

Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens.

Laddy DJ, Yan J, Kutzler M, Kobasa D, Kobinger GP, Khan AS, Greenhouse J, Sardesai NY, Draghia-Akli R, Weiner DB.

PLoS One. 2008 Jun 25;3(6):e2517. doi: 10.1371/journal.pone.0002517.

49.

Characterization of a trypsin-dependent avian influenza H5N1-pseudotyped HIV vector system for high throughput screening of inhibitory molecules.

Ao Z, Patel A, Tran K, He X, Fowke K, Coombs K, Kobasa D, Kobinger G, Yao X.

Antiviral Res. 2008 Jul;79(1):12-8. doi: 10.1016/j.antiviral.2008.02.001. Epub 2008 Mar 6.

50.

Partial protection against H5N1 influenza in mice with a single dose of a chimpanzee adenovirus vector expressing nucleoprotein.

Roy S, Kobinger GP, Lin J, Figueredo J, Calcedo R, Kobasa D, Wilson JM.

Vaccine. 2007 Sep 28;25(39-40):6845-51. Epub 2007 Aug 6.

Supplemental Content

Loading ...
Support Center